Nefazodone

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Mechanism only
Half-life: 2–4 h; Approximate, in adults. Detail in 01.

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: nefazodone · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

5-HT2A blockade blunts effects; strong CYP3A4 inhibitor (minor psilocin route).

Human data with psilocybin: None known: no published human data with psilocybin
Half-life: 2–4 h / hydroxynefazodone 1.5–4 h, mCPP 4–8 h, triazole-dione 18 h (FDA label, checked 2026-09-30)

Evidence types on this record

ThMechanism only (theoretical)

2 listed · counted on reports

Blocks 5-HT2A (may blunt effects): Blocks the 5-HT2A receptor, the main receptor psilocybin acts through. Can reduce or block the psilocybin effect. Sources [1]
Serotonergic: Increases serotonin activity, for example by blocking its reuptake or releasing it. Psilocybin acts on serotonin receptors, so effects can add together. With antidepressant use, the psilocybin response can be weaker. Sources [1]

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

None linked

No condition named in state rules is linked to this medication.